These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21742586)

  • 1. Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
    Giuntoli RL; Bristow RE; Diaz-Montes TP; Armstrong DK
    J Chemother; 2011 Jun; 23(3):163-7. PubMed ID: 21742586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
    Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
    Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
    Villella J; Marchetti D; Odunsi K; Rodabaugh K; Driscoll DL; Lele S
    Gynecol Oncol; 2004 Dec; 95(3):539-45. PubMed ID: 15581960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
    Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
    Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
    Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
    Kose MF; Sufliarsky J; Beslija S; Saip P; Tulunay G; Krejcy K; Minarik T; Fitzthum E; Hayden A; Melemed A
    Gynecol Oncol; 2005 Feb; 96(2):374-80. PubMed ID: 15661224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
    Richardson DL; Backes FJ; Seamon LG; Zanagnolo V; O'Malley DM; Cohn DE; Fowler JM; Copeland LJ
    Gynecol Oncol; 2008 Dec; 111(3):461-6. PubMed ID: 18829088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
    Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
    Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
    Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Pfisterer J; Schroeder W; Blohmer JU; Kimmig R; Moebus V; Quaas J
    Ann Oncol; 2001 Aug; 12(8):1115-20. PubMed ID: 11583193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
    Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
    Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
    J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
    Eisenhauer EL; Zanagnolo V; Cohn DE; Salani R; O'Malley DM; Sutton G; Callahan MJ; Cobb B; Fowler JM; Copeland LJ
    Gynecol Oncol; 2014 Aug; 134(2):262-6. PubMed ID: 24910452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
    Rose PG; Mossbruger K; Fusco N; Smrekar M; Eaton S; Rodriguez M
    Gynecol Oncol; 2003 Jan; 88(1):17-21. PubMed ID: 12504621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
    Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
    Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.
    Nasr FL; Chahine GY; Kattan JG; Farhat FS; Mokaddem WT; Tueni EA; Dagher JE; Ghosn MG
    Clin Breast Cancer; 2004 Jun; 5(2):117-22; discussion 123-4. PubMed ID: 15245614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
    Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
    Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
    Mäenpää JU; Grénman SE; Jalkanen JT; Kuoppala TA; Leminen AO; Puistola US; Vuolo-Merilä PM; Yliskoski MH
    Gynecol Oncol; 2006 Apr; 101(1):114-9. PubMed ID: 16266743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.